Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Aug 18;1(8):530-1.
doi: 10.1021/cn100070s.

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD)

Craig W Lindsley
Clinical Trial

(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD)

Craig W Lindsley. ACS Chem Neurosci. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of Citalopram, Escitalopram, and TC-5214.
See this image and copyright information in PMC

References

    1. Decision Resources (2009) Report: New Devleopments in Major Depressive Disorder, August 2009, Decision Resources, Waltham, MA.
    1. Lindsley C. W. (2010) The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing. ACS Chem. Neurosci. 1, 407–408. - PMC - PubMed
    1. For more information, see www.targacept.com
    1. For more information, see www.astrazeneca.com
    1. Lippiello P. M.; Beaver J. S.; Gatto G. J.; James J. W.; Jordan K. G.; Traina V. M.; Xie J.; Bencherif M. (2008) TC-5214 (S)-(+)-Mecamylamine: A neuronal nictonicv receptor modulator with antidepressant activity. CNS Neurosci.Ther. 14, 266–277. - PMC - PubMed

MeSH terms